

November 11, 2020

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Outcome of Board Meeting held on November 11, 2020.

The Board of Directors of the Company at its meeting held today, November 11, 2020, has, inter alia, considered and approved:-

1. the Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.
2. a Second Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed **November 24, 2020** as the **Record Date** for the purpose of payment of Second Interim Dividend and the same will be paid on or before **December 4, 2020**.
3. the transfer of business undertaking of Auronext Pharma Private Limited, a wholly owned subsidiary of the Company, on a going concern basis, to Eugia Pharma Specialities Limited, another wholly owned step-down subsidiary of the Company, through execution of a business transfer agreement. Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, are provided at **Annexure-"A"**.

We also enclose a copy of the Press Release on Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2020.

The Board meeting commenced at 2.30 p.m. and concluded at 5.20 p.m.

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**


B. Adi Reddy
Company Secretary



Enclosures: as above.